PROK · XBRL financial data

Prokidney financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PROK's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	46	82	107	128	114
General and administrative	9	71	45	56	52
Total operating expenses	55	153	152	184	166
Operating income (loss)	(55)	(153)	(152)	(184)	(165)
Interest expense	0	0	0	0	0
Income tax expense (benefit)	0	1	6	(1)	0
Net income (loss)	(55)	—	(35)	(61)	(69)
Earnings per share, basic USD per share	—	(0.23)	—	—	—
Earnings per share, diluted USD per share	—	(0.23)	—	—	—
Weighted average shares, basic millions of shares	—	62	—	—	—
Weighted average shares, diluted millions of shares	—	62	—	—	—

Fiscal years (PROK's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	0	490	61	99	109
Total current assets	1	505	374	396	281
Property and equipment, net	11	11	42	42	51
Right-of-use asset	1	2	4	3	4
Total assets	251	518	421	441	336
Accounts payable	3	3	5	4	1
Accrued liabilities	9	7	18	31	29
Total current liabilities	2	11	25	36	31
Lease liability, non-current	1	2	4	2	3
Total liabilities	10	13	29	39	35
Accumulated deficit	(8)	(1,104)	(1,140)	(1,201)	(1,270)
Total stockholders' equity	(8)	(1,097)	(1,103)	(995)	(1,011)
Total liabilities and equity	251	518	421	441	336

Fiscal years (PROK's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(55)	—	(35)	(61)	(69)
Stock-based compensation	1	74	31	29	25
Depreciation and amortization	2	3	4	5	7
Net cash from operating activities	(50)	(77)	(90)	(126)	(120)
Purchases of property and equipment	5	2	34	30	15
Net cash from investing activities	(5)	(2)	(330)	20	104
Proceeds from issuing common stock	0	543	0	144	24
Share repurchases	0	0	9	0	0
Net cash from financing activities	71	549	(10)	144	26
Net change in cash	16	470	(430)	38	9

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Prokidney	75	not reported	(40)*	not reported	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Parabilis Medicines	1,087	0.1	not reported	121.9M	—	Q2 FY26 10-QJun 30, 2026
Sutro Biopharma	54	9.8	(38)*	16.6M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
PDS Biotechnology	5.6	not reported	(2.8)*	56.0M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
iBio	56	0*	(6.2)*	64.3M	14.1 quarters	Q4 FY26 10-KJun 30, 2026
Medicinova	25	0.5	(1.9)*	49.2M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Lifevantage	15	42*	4.8*	12.5M	—	Q4 FY26 10-KJun 30, 2026
Veru	24	not reported	(5.5)*	17.1M	4.4 quarters	Q3 FY26 10-QJun 30, 2026
Avalo Therapeutics	85	not reported	(20)*	53.6M	20.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.